AmbioPharm

Executive Summary

AmbioPharm is a contract development and manufacturing organization (CDMO) specializing in peptide active pharmaceutical ingredients (APIs). Founded in 2006 and headquartered in North Augusta, South Carolina, the company operates FDA-inspected facilities in both the United States and China, offering development and manufacturing services from pre-clinical through commercial stages. As a privately held company, AmbioPharm is well-positioned to capitalize on the growing demand for peptide-based therapeutics, driven by increasing adoption in oncology, metabolic disorders, and other therapeutic areas. Its dual-site strategy provides supply chain resilience and cost advantages, while its regulatory-compliant facilities enable it to serve a global client base. The company's focus on peptide APIs, a high-growth niche within the CDMO market, supports its long-term value proposition, though its private nature limits visibility into financial performance and near-term growth catalysts.

Upcoming Catalysts (preview)

• 2026Facility Expansion or Capacity Addition60% success
• TBDNew Long-Term Supply Agreement with Major Pharma50% success
• 2026Regulatory Approval for New Manufacturing Line (e.g., FDA or NMPA)70% success